Adrenergic drugs, also named as sympathomimetic drugs stimulate a response from the adrenergic receptors. This drug is used to stimulate the sympathetic nervous system located in the chest and lower back region of the spinal cord. These drugs stimulate the chemical messenger epinephrine and norepinephrine from the adrenal gland, or replicate the action of these chemical messengers. There are five main categories of adrenergic receptors as α₁, α₂, β₁, β₂, and β₃. Adrenergic drugs are used to increase the breathing rate, heartbeat, sweating, urine flow, and prevent bleeding. There are three major types of adrenergic drugs most commonly used such as Bronchodilators, vasopressors, and cardiac stimulators. This drug is used in the treatment of various life-threatening conditions including chronic obstructive pulmonary diseases (COPD), asthma, cardiac arrest, shock, and allergic reactions.
COVID-19 Scenario Analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
As the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries across the globe with the “World Health Organization” announcing it a public health emergency. The global impacts of the COVID-19 pandemic are already starting to be felt, and will significantly affect the adrenergic drug market in 2020. COVID-19 can affect the global economy in three main ways by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:
Globally, North America holds the largest market share and dominates the adrenergic drug market. This is attributed to factors such as growing patient population, increasing product launches, presence of major market player and increasing chronic disorder associated patient population. However, Europe accounts for the second largest share in the adrenergic drug market. This is due to increase in product approvals, rise in awareness, adoption of expansion strategies by global manufacturers and strategic acquisition of manufacturers as well as increase in R&D activities. Whereas, Asia-Pacific is expected to witness the highest adrenergic drug market growth rate. This is due to large number of patient diagnosed with asthma and COPD, rising healthcare expenditure, and increasing healthcare facilities
“WHO” reported that, in 2017, around 251 million individuals were affected by chronic obstructive pulmonary disease across the globe. “American Heart Association” (AHA) reported that globally, around 350,000 cases of cardiac arrest are reported at hospital set ups every year.
Factors that drive the growth of the adrenergic drug market include increasing new product development, rising incidences of chronic obstructive pulmonary diseases (COPD), asthma, and cardiac arrest, increasing patient population, rising applications of adrenergic drugs for a variety of disease indications, technological advancements, increase in incidence of chronic diseases, rising awareness among the individuals regarding timely diagnosis, rise in strategic collaborations, and rising products approvals by regulatory authorities. However, factors that restrain the growth of adrenergic drug market include side effects of adrenergic drugs includes irregular heartbeat, high blood pressure as well as chest pain and high cost of product development. The opportunities available for adrenergic drug market such as reduction in the cost of adrenergic drug product, introducing advanced product with less or no side effect
New Product launch to flourish the market:
Major Key manufacturers have been focusing on increasing R&D activities and producing new product solution for specific applications as there are varying demands based on the utilization. Leading market players have determined how improved accuracy can be influential in many applications. In 2019, “Boehringer Ingelheim GmbH” has launched “StioltoTM Respimat ® Inhalation Spray” is a prescription medicine used for long term, two puffs every day, in controlling symptoms in adults with chronic obstructive pulmonary disease (COPD). COPD is a chronic lung disease that includes chronic bronchitis, emphysema, or both.
In 2018, “Merck & Co., Inc.” has launched a new adrenergic product such as “L-798106”. This was among the first prostanoid receptor EP3-selective antagonists. It has been used in multiple studies to tease out EP3 agonist activity, both in vitro and in vivo. It successfully blocks the actions of sulprostone, an EP3-selective agonist, and it helped show that the vascular contraction effect of PGE2 is due to its prostanoid EP3 agonist activity.
In 2018, “Teva Pharmaceutical” has launched “ AIRDUO® DIGIHALER™” is a prescription medicine used to control symptoms of asthma and to prevent symptoms such as wheezing in people 12 years of age and older.
Key benefits of the report:
- This study presents the analytical depiction of the global adrenergic drug market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global adrenergic drug market share.
- The current market is quantitatively analyzed to highlight the global adrenergic drug market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global adrenergic drug market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Adrenergic Drug Market research report:
- Who are the leading market players active in adrenergic drug market?
- What are the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that will help in taking further strategic steps?
Adrenergic Drug Market Report Highlights
| Aspects | Details |
 By Drug Class · |
|
 By Route of Administration |
|
 By Disease Indication |
|
 By Distribution Channel · |
|
 By Region |
|
 Key Market Players | Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Mylan Pharmaceutical Inc, AstraZeneca plc, Merck and Co., Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Cipla, GlaxoSmithKline plc |
Loading Table Of Content...
